Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...

When patients visit Womack Army Medical Center (WAMC) and the outlying clinics, they typically interact with doctors, nurses, ...

Huntley paced the field with 98 team points, placing first in the overall competition at the 48th annual Tiger Invitational ...

A Umatilla woman battling cancer found a dog on Facebook to help her through treatment, but she says it was all part of a lie ...

Coramitug is designed to clear toxic protein deposits from the heart, offering a new approach to treating ATTR cardiomyopathy ...

Expression Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a curative autologous stem cell therapy for hemophilia A, today announced that the U.S. Food and Drug ...

Right breast cancer pathway discipline embeds testing early to guide treatment decisions and improve care consistency across health systems.

Always a Runner, trained by Chad Brown and ridden by Jose Ortiz, won the 2026 Kentucky Oaks at Churchill Downs in Louisville, ...

Monitoring a constant stream of data doesn’t help people make health-related decisions and can lead to confusion and needless ...

The Phase 1/2 FUNCTION-DMD study will enroll ambulatory patients and is designed to evaluate safety, tolerability, and efficacy, including dystrophin protein expression and functional outcomes. "The ...

Namodenoson is a highly selective A3 adenosine receptor (A3AR) agonist, which has shown a compelling safety profile and demonstrated anti-tumor activity in preclinical pancreatic cancer models. The ...

Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Coramitug is being evaluated by Novo Nordisk in the ongoing Phase 3 ...